{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T19:46:43Z","timestamp":1767988003083,"version":"3.49.0"},"reference-count":92,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.clcc.2023.12.003","type":"journal-article","created":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T22:08:54Z","timestamp":1702678134000},"page":"4-13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Clinical Management of Gastrointestinal and Liver Toxicities of Immune Checkpoint Inhibitors"],"prefix":"10.1016","volume":"23","author":[{"given":"Kevin","family":"Mok","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent Wai-Sun","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigette","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1277-9595","authenticated-orcid":false,"given":"Rashid","family":"Lui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clcc.2023.12.003_bib0001","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3389\/fonc.2018.00086","article-title":"Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations","volume":"8","author":"Seidel","year":"2018","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.clcc.2023.12.003_sbref0002","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.cell.2020.06.001","article-title":"Molecular pathways of colon inflammation induced by cancer immunotherapy","volume":"182","author":"Luoma","year":"2020","journal-title":"Cell"},{"issue":"230","key":"10.1016\/j.clcc.2023.12.003_bib0003","doi-asserted-by":"crossref","first-page":"230ra45","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.clcc.2023.12.003_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102440","article-title":"Immune checkpoint inhibitor-induced diarrhea and colitis: incidence and Management. A systematic review and meta-analysis","volume":"109","author":"Nielsen","year":"2022","journal-title":"Cancer Treat Rev"},{"issue":"7","key":"10.1016\/j.clcc.2023.12.003_bib0005","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1634\/theoncologist.2015-0509","article-title":"Immune checkpoint inhibitors: review and management of endocrine adverse events","volume":"21","author":"Gonz\u00e1lez-Rodr\u00edguez","year":"2016","journal-title":"Oncologist"},{"issue":"17","key":"10.1016\/j.clcc.2023.12.003_bib0006","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clcc.2023.12.003_bib0007","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1016\/j.cgh.2021.06.038","article-title":"Management of gastrointestinal side effects of immune checkpoint inhibitors","volume":"19","author":"Lui","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.clcc.2023.12.003_bib0008","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S1470-2045(17)30231-0","article-title":"Ipilimumab 10 mg\/kg versus ipilimumab 3 mg\/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial","volume":"18","author":"Ascierto","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clcc.2023.12.003_bib0009","article-title":"Interaction between gut microbiota and immune checkpoint inhibitor-related colitis","volume":"13","author":"Zhou","year":"2022","journal-title":"Front Immunol"},{"issue":"16","key":"10.1016\/j.clcc.2023.12.003_bib0010","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1002\/cncr.32966","article-title":"Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor-induced colitis","volume":"126","author":"Grover","year":"2020","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.clcc.2023.12.003_bib0011","doi-asserted-by":"crossref","first-page":"e933","DOI":"10.1200\/JOP.19.00672","article-title":"Safety of immune checkpoint inhibitors in patients with pre-existing inflammatory bowel disease and microscopic colitis","volume":"16","author":"Grover","year":"2020","journal-title":"JCO Oncol Pract"},{"issue":"6","key":"10.1016\/j.clcc.2023.12.003_bib0012","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/annonc\/mdx108","article-title":"Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab","volume":"28","author":"Chaput","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2023.12.003_bib0013","doi-asserted-by":"crossref","first-page":"10391","DOI":"10.1038\/ncomms10391","article-title":"Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis","volume":"7","author":"Dubin","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.clcc.2023.12.003_bib0014","article-title":"Correlation of the gut microbiome and immune-related adverse events in gastrointestinal cancer patients treated with immune checkpoint inhibitors","volume":"13","author":"Zhang","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"issue":"2","key":"10.1016\/j.clcc.2023.12.003_bib0015","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1093\/jnci\/djaa057","article-title":"Association of antibiotic exposure with survival and toxicity in patients with melanoma receiving immunotherapy","volume":"113","author":"Mohiuddin","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.clcc.2023.12.003_bib0016","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/s40425-019-0714-x","article-title":"Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis","volume":"7","author":"Abu-Sbeih","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"8","key":"10.1016\/j.clcc.2023.12.003_bib0017","first-page":"358","article-title":"Diagnosis and management of immune checkpoint inhibitor colitis","volume":"17","author":"Hashash","year":"2021","journal-title":"Gastroenterol Hepatol"},{"issue":"36","key":"10.1016\/j.clcc.2023.12.003_bib0018","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.clcc.2023.12.003_bib0019","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Electronic address: clinicalguidelines@esmo.org. Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.clcc.2023.12.003_bib0020","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1053\/j.gastro.2020.08.063","article-title":"AGA clinical practice update on diagnosis and management of immune checkpoint inhibitor colitis and hepatitis: expert review","volume":"160","author":"Dougan","year":"2021","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.clcc.2023.12.003_bib0021","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1093\/ibd\/izy104","article-title":"Endoscopic and histologic features of immune checkpoint inhibitor-related colitis","volume":"24","author":"Wang","year":"2018","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"10.1016\/j.clcc.2023.12.003_bib0022","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41416-020-0882-y","article-title":"Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way?","volume":"123","author":"Cheung","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clcc.2023.12.003_bib0023","unstructured":"U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES. Common terminology criteria for adverse events (CTCAE) version 5.0 [Internet]. 2017. Accessed February 19, 2023. Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf."},{"issue":"2","key":"10.1016\/j.clcc.2023.12.003_bib0024","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001329","article-title":"Diagnostic utility of CT for suspected immune checkpoint inhibitor enterocolitis","volume":"8","author":"Durbin","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.clcc.2023.12.003_bib0025","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-018-0411-1","article-title":"Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis","volume":"6","author":"Abu-Sbeih","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.clcc.2023.12.003_bib0026","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002058","article-title":"Fecal calprotectin concentration to assess endoscopic and histologic remission in patients with cancer with immune-mediated diarrhea and colitis","volume":"9","author":"Zou","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"12","key":"10.1016\/j.clcc.2023.12.003_bib0027","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1111\/apt.15263","article-title":"Systematic review and case series: flexible sigmoidoscopy identifies most cases of checkpoint inhibitor-induced colitis","volume":"49","author":"Wright","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.clcc.2023.12.003_bib0028","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1080\/00365521.2019.1594356","article-title":"Upper gastrointestinal symptoms and associated endoscopic and histological features in patients receiving immune checkpoint inhibitors","volume":"54","author":"Tang","year":"2019","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.clcc.2023.12.003_bib0029","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12885-015-1074-7","article-title":"Ipilimumab and immune-mediated adverse events: a case report of anti-CTLA4 induced ileitis","volume":"15","author":"Venditti","year":"2015","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.clcc.2023.12.003_bib0030","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000451","article-title":"Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis","volume":"8","author":"Mooradian","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"5","key":"10.1016\/j.clcc.2023.12.003_bib0031","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1097\/PAS.0000000000000829","article-title":"Histopathologic features of colitis due to immunotherapy with anti-PD-1 antibodies","volume":"41","author":"Chen","year":"2017","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.clcc.2023.12.003_bib0032","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1186\/s40425-019-0756-0","article-title":"Budesonide treatment for microscopic colitis from immune checkpoint inhibitors","volume":"7","author":"Hughes","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"11","key":"10.1016\/j.clcc.2023.12.003_bib0033","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003277","article-title":"Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study","volume":"9","author":"Zou","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.clcc.2023.12.003_bib0034","unstructured":"Infliximab label [Internet]. U.S. Food and Drug Administration. 10\/2021. Accessed February 24, 2023. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/103772s5401lbl.pdf."},{"key":"10.1016\/j.clcc.2023.12.003_bib0035","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2016-216641","article-title":"Vedolizumab: a novel treatment for ipilimumab-induced colitis","volume":"2016","author":"Hsieh","year":"2016","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.clcc.2023.12.003_bib0036","unstructured":"Infliximab or vedolizumab in treating immune checkpoint inhibitor-related colitis in patients with genitourinary cancer or melanoma [Internet]. Accessed February 24, 2023. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04407247."},{"issue":"3","key":"10.1016\/j.clcc.2023.12.003_sbref0037","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1053\/j.gastro.2020.10.029","article-title":"Efficacy and outcome of tofacitinib in immune checkpoint inhibitor colitis","volume":"160","author":"Bishu","year":"2021","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.clcc.2023.12.003_bib0038","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJMc2031717","article-title":"Ustekinumab for refractory colitis associated with immune checkpoint inhibitors","volume":"384","author":"Thomas","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.clcc.2023.12.003_bib0039","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1038\/s41591-018-0238-9","article-title":"Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis","volume":"24","author":"Wang","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.clcc.2023.12.003_bib0040","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.907591","article-title":"Immune-mediated hepatitis during immune checkpoint inhibitor cancer immunotherapy: lessons from autoimmune hepatitis and liver immunology","volume":"13","author":"Hercun","year":"2022","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.clcc.2023.12.003_bib0041","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1111\/bcp.14433","article-title":"Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapy","volume":"86","author":"Mangan","year":"2020","journal-title":"Br J Clin Pharmacol"},{"issue":"19","key":"10.1016\/j.clcc.2023.12.003_bib0042","doi-asserted-by":"crossref","first-page":"7052","DOI":"10.1002\/cam4.3378","article-title":"Pattern and impact of hepatic adverse events encountered during immune checkpoint inhibitors: a territory-wide cohort study","volume":"9","author":"Chan","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.clcc.2023.12.003_bib0043","doi-asserted-by":"crossref","first-page":"4871","DOI":"10.2147\/CMAR.S202017","article-title":"Ipilimumab and nivolumab as first-line treatment of patients with renal cell carcinoma: the evidence to date","volume":"12","author":"Sheng","year":"2020","journal-title":"Cancer Manag Res"},{"issue":"32","key":"10.1016\/j.clcc.2023.12.003_bib0044","doi-asserted-by":"crossref","first-page":"5376","DOI":"10.3748\/wjg.v27.i32.5376","article-title":"Immune checkpoint inhibitor-related hepatotoxicity: a review","volume":"27","author":"Remash","year":"2021","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10.1016\/j.clcc.2023.12.003_bib0045","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.clcc.2023.12.003_bib0046","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1200\/EDBK_100013","article-title":"Gastrointestinal and hepatic toxicities of checkpoint inhibitors: algorithms for management","volume":"38","author":"Grover","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"6","key":"10.1016\/j.clcc.2023.12.003_bib0047","article-title":"Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort","volume":"5","author":"Hountondji","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.clcc.2023.12.003_bib0048","article-title":"Immune-mediated hepatitis induced by immune checkpoint inhibitors: current updates and future perspectives","volume":"13","author":"Liu","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clcc.2023.12.003_bib0049","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ctrv.2016.02.003","article-title":"Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy","volume":"45","author":"Eigentler","year":"2016","journal-title":"Cancer Treat Rev"},{"issue":"10","key":"10.1016\/j.clcc.2023.12.003_bib0050","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005635","article-title":"Systematic comparison with autoimmune liver disease identifies specific histological features of immune checkpoint inhibitor-related adverse events","volume":"10","author":"Coukos","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"6","key":"10.1016\/j.clcc.2023.12.003_bib0051","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jhep.2018.01.033","article-title":"Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors","volume":"68","author":"De Martin","year":"2018","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.clcc.2023.12.003_bib0052","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2020.06.016","article-title":"Severe immune-related hepatitis induced by immune checkpoint inhibitors: clinical features and management proposal","volume":"45","author":"Gauci","year":"2021","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"3","key":"10.1016\/j.clcc.2023.12.003_bib0053","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/hep.32215","article-title":"Effect of corticosteroid dosing on outcomes in high-grade immune checkpoint inhibitor hepatitis","volume":"75","author":"Li","year":"2022","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.clcc.2023.12.003_bib0054","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/liv.13953","article-title":"Impact of dose and duration of corticosteroid on the risk of hepatitis flare in patients with chronic hepatitis B","volume":"39","author":"Wong","year":"2019","journal-title":"Liver Int"},{"issue":"3","key":"10.1016\/j.clcc.2023.12.003_bib0055","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jhep.2016.11.015","article-title":"Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids","volume":"66","author":"Ziemer","year":"2017","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.clcc.2023.12.003_bib0056","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","article-title":"Electronic address: easloffice@easloffice.eu, clinical practice guideline panel: chair:, panel members, EASL governing board representative: EASL clinical practice guidelines: drug-induced liver injury","volume":"70","year":"2019","journal-title":"J Hepatol"},{"issue":"suppl_4","key":"10.1016\/j.clcc.2023.12.003_bib0057","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.clcc.2023.12.003_bib0058","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.3390\/ijms19082199","article-title":"Harmful effects and potential benefits of anti-tumor necrosis factor (TNF)-\u03b1 on the Liver","volume":"19","author":"Lopetuso","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.clcc.2023.12.003_bib0059","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/s41379-018-0013-y","article-title":"Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury","volume":"31","author":"Zen","year":"2018","journal-title":"Mod Pathol"},{"issue":"9","key":"10.1016\/j.clcc.2023.12.003_bib0060","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/1346-8138.16432","article-title":"Safety and effectiveness of nivolumab in Japanese patients with malignant melanoma: Final analysis of a post-marketing surveillance","volume":"49","author":"Uhara","year":"2022","journal-title":"J Dermatol"},{"issue":"1","key":"10.1016\/j.clcc.2023.12.003_bib0061","doi-asserted-by":"crossref","first-page":"43","DOI":"10.4103\/jpgm.JPGM_793_20","article-title":"Pembrolizumab-induced large duct cholangiopathy: diagnosis and follow.up imaging","volume":"67","author":"Chatterjee","year":"2021","journal-title":"J Postgrad Med"},{"issue":"4","key":"10.1016\/j.clcc.2023.12.003_bib0062","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2017-000268","article-title":"Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury","volume":"2","author":"Doherty","year":"2017","journal-title":"ESMO Open"},{"issue":"1S Suppl 1","key":"10.1016\/j.clcc.2023.12.003_bib0063","doi-asserted-by":"crossref","first-page":"e858","DOI":"10.1097\/MEG.0000000000002280","article-title":"Immune-related cholangitis induced by immune checkpoint inhibitors: a systematic review of clinical features and management","volume":"33","author":"Pi","year":"2021","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.clcc.2023.12.003_bib0064","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s10637-017-0453-0","article-title":"Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer","volume":"35","author":"Kawakami","year":"2017","journal-title":"Invest New Drugs"},{"issue":"9","key":"10.1016\/j.clcc.2023.12.003_bib0065","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1111\/jgh.15797","article-title":"Gastrointestinal: immune-related sclerosing cholangitis with pembrolizumab: imaging and histological features","volume":"37","author":"Suzuki","year":"2022","journal-title":"J Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.clcc.2023.12.003_bib0066","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/his.14000","article-title":"Immune-related adverse reactions in the hepatobiliary system: second-generation check-point inhibitors highlight diverse histological changes","volume":"76","author":"Zen","year":"2020","journal-title":"Histopathology"},{"issue":"1","key":"10.1016\/j.clcc.2023.12.003_bib0067","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/liv.15340","article-title":"Immune checkpoint inhibitor-related cholangiopathy: novel clinicopathological description of a multi-centre cohort","volume":"43","author":"Berry","year":"2023","journal-title":"Liver Int"},{"issue":"1","key":"10.1016\/j.clcc.2023.12.003_bib0068","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2020-000487","article-title":"Case of nivolumab-induced sclerosing cholangitis: lessons from long-term follow-up","volume":"7","author":"McClure","year":"2020","journal-title":"BMJ Open Gastroenterol"},{"issue":"3","key":"10.1016\/j.clcc.2023.12.003_bib0069","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/jgh3.12875","article-title":"Pancreatic adverse events in patients treated with immune checkpoint inhibitors","volume":"7","author":"Hana","year":"2023","journal-title":"JGH Open"},{"issue":"4","key":"10.1016\/j.clcc.2023.12.003_bib0070","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s00262-022-03295-1","article-title":"Pancreatic involvement due to immune checkpoint inhibitors: a proposed classification","volume":"72","author":"Ashkar","year":"2023","journal-title":"Cancer Immunol Immunother"},{"issue":"7","key":"10.1016\/j.clcc.2023.12.003_bib0071","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/CJI.0000000000000472","article-title":"Immune checkpoint inhibitor-related pancreatitis: a case series, review of the literature and an expert opinion","volume":"46","author":"Kramer","year":"2023","journal-title":"J Immunother"},{"key":"10.1016\/j.clcc.2023.12.003_bib0072","article-title":"Immunotherapy-associated pancreatic adverse events: current understanding of their mechanism, diagnosis, and management","volume":"11","author":"Liu","year":"2021","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.clcc.2023.12.003_bib0073","first-page":"14","article-title":"From lipase elevation to diabetes \u2013 pancreatic involvement during immune checkpoint inhibition","volume":"5","author":"Simon","year":"2023","journal-title":"J Cell Immunol"},{"issue":"1","key":"10.1016\/j.clcc.2023.12.003_bib0074","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40425-019-0502-7","article-title":"Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury","volume":"7","author":"Abu-Sbeih","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.clcc.2023.12.003_bib0075","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1157805","article-title":"Endocrine side effects of immune checkpoint inhibitors","volume":"14","author":"Cardona","year":"2023","journal-title":"Front Endocrinol"},{"issue":"3","key":"10.1016\/j.clcc.2023.12.003_bib0076","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/cncr.34543","article-title":"Immune checkpoint inhibitor gastritis is often associated with concomitant enterocolitis, which impacts the clinical course","volume":"129","author":"Haryal","year":"2023","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.clcc.2023.12.003_bib0077","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1111\/jgh.16349","article-title":"Serious immune-related upper gastrointestinal toxicity of immune checkpoint inhibitors: a multicenter case series","volume":"38","author":"Bresteau","year":"2023","journal-title":"J Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.clcc.2023.12.003_bib0078","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1111\/jgh.15788","article-title":"Gastrointestinal: pembrolizumab-induced gastric ulcer occurring as an immune-related adverse event","volume":"37","author":"Terasaki","year":"2022","journal-title":"J Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.clcc.2023.12.003_bib0079","doi-asserted-by":"crossref","first-page":"191","DOI":"10.5858\/arpa.2019-0700-OA","article-title":"Immune checkpoint inhibitor-induced upper gastrointestinal tract inflammation shows morphologic similarities to, but is immunologically distinct from, helicobacter pylori gastritis and celiac disease","volume":"145","author":"Irshaid","year":"2021","journal-title":"Arch Pathol Lab Med"},{"issue":"8","key":"10.1016\/j.clcc.2023.12.003_bib0080","doi-asserted-by":"crossref","first-page":"896","DOI":"10.6004\/jnccn.2020.7675","article-title":"Clinicopathologic features, treatment response, and outcomes of immune checkpoint inhibitor-related esophagitis","volume":"19","author":"Panneerselvam","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"issue":"12","key":"10.1016\/j.clcc.2023.12.003_bib0081","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.6004\/jnccn.2020.7697","article-title":"Clinical characteristics and outcomes of oral mucositis associated with immune checkpoint inhibitors in patients with cancer","volume":"19","author":"Jacob","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"issue":"4","key":"10.1016\/j.clcc.2023.12.003_bib0082","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1136\/flgastro-2018-101146","article-title":"Immunotherapy-related hepatitis: real-world experience from a tertiary centre","volume":"10","author":"Cheung","year":"2019","journal-title":"Frontline Gastroenterol"},{"issue":"6","key":"10.1016\/j.clcc.2023.12.003_bib0083","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s00535-020-01677-9","article-title":"Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignancies","volume":"55","author":"Mizuno","year":"2020","journal-title":"J Gastroenterol"},{"issue":"4","key":"10.1016\/j.clcc.2023.12.003_bib0084","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.pan.2019.04.015","article-title":"Incidence of pancreatitis with the use of immune checkpoint inhibitors (ICI) in advanced cancers: A systematic review and meta-analysis","volume":"19","author":"George","year":"2019","journal-title":"Pancreatology"},{"issue":"6","key":"10.1016\/j.clcc.2023.12.003_bib0085","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","article-title":"Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer","volume":"6","author":"Dolladille","year":"2020","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.clcc.2023.12.003_bib0086","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/annonc\/mdx642","article-title":"Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma","volume":"29","author":"Pollack","year":"2018","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.clcc.2023.12.003_bib0087","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","volume":"28","author":"Menzies","year":"2017","journal-title":"Ann Oncol"},{"issue":"30","key":"10.1016\/j.clcc.2023.12.003_bib0088","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1200\/JCO.19.00320","article-title":"Resumption of immune checkpoint inhibitor therapy after immune-mediated colitis","volume":"37","author":"Abu-Sbeih","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2023.12.003_bib0089","first-page":"11","article-title":"Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma","volume":"10","author":"Berman","year":"2010","journal-title":"Cancer Immun"},{"issue":"17","key":"10.1016\/j.clcc.2023.12.003_bib0090","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1158\/1078-0432.CCR-09-1024","article-title":"A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma","volume":"15","author":"Weber","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.clcc.2023.12.003_bib0091","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.cgh.2022.03.050","article-title":"Retreatment with immune checkpoint inhibitors after a severe immune-related hepatitis: results from a prospective multicenter study","volume":"21","author":"Riveiro-Barciela","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.clcc.2023.12.003_bib0092","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1111\/j.1440-1746.2012.07194.x","article-title":"Digestive cancer management in Asia: position statements: a report on GI Oncology Summit in 2011","volume":"27","author":"Sung","year":"2012","journal-title":"J Gastroenterol Hepatol"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002823001251?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002823001251?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:09:42Z","timestamp":1761520182000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1533002823001251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":92,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S1533002823001251"],"URL":"https:\/\/doi.org\/10.1016\/j.clcc.2023.12.003","relation":{},"ISSN":["1533-0028"],"issn-type":[{"value":"1533-0028","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Management of Gastrointestinal and Liver Toxicities of Immune Checkpoint Inhibitors","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clcc.2023.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}